Pregabalin 90-day Supply With Refills Under Federal Controlled-Substance Rules
Pregabalin is classified as a Schedule V controlled substance in the United States. [1] A prescription for a Schedule V controlled substance may be refilled when authorized by a practitioner for a legitimate medical purpose, and federal DEA/CSA regulations do not specify limits on the number of refills for Schedule V prescriptions. [2], [3]
Federal Refill Limits for Schedule V Controlled Substances
DEA regulations and the CSA provide that Schedule V refills are permitted when issued for a medical purpose in the usual course of professional practice. [2], [3] DEA’s Practitioner’s Manual states that the CSA and DEA regulations do not address limits for a Schedule V refill. [2]
Quantity Duration on a Single Prescription
Federal controlled-substance rules cited by DEA’s Practitioner’s Manual address refill limits for Schedule III and IV but do not identify a federal day-supply cap specifically for Schedule V prescriptions. [2] A 90-day supply with up to two refills is not prohibited by the DEA/CSA refill-limit framework for Schedule V controlled substances, provided the prescription is for a legitimate medical purpose in the usual course of professional practice. [2], [3]
State Law and Program-Level Constraints
State controlled-substance laws and any applicable state prescription monitoring program (PMP) requirements can impose additional constraints beyond federal DEA/CSA rules. [2]
Practical Prescribing Requirement
The prescription should be issued with appropriate controlled-substance prescription elements (including required patient and practitioner identifiers and prescription details) consistent with DEA requirements. [2]
Answer to the Prescribing Scenario
Yes. A stable adult patient on pregabalin can be prescribed a 90-day supply with up to two refills under the federal Schedule V framework, assuming authorization for refills is included and the prescription is issued for a legitimate medical purpose in the usual course of professional practice. [1], [2], [3]
Relevant Clinical Safety Note
Pregabalin has abuse and misuse potential consistent with CNS-active medications, so ongoing evaluation for misuse or diversion is clinically appropriate. [1]